Loading patent…
AssigneesInstitut Curie, Institut National de la Sante et de la Recherche Medicale, Centre National De La Recherche Scientifique, President and Fellows of Harvard College
InventorsRAPHAËL RODRIGUEZ, STÉPHANIE SOLIER, SÉBASTIAN MÜLLER, TERESA TATIANA CAÑEQUE, JESSALYN UBELLACKER
Estimating the term…
The invention relates to a pharmaceutical composition for use in a method for the treatment of cancer and/or immune deficiency diseases and/or infectious diseases, comprising a metal ion and optionally hyaluronate (HA) or a hyaluronate conjugate, wherein said method comprises the intralymphatic administration of the pharmaceutical composition to a subject. The invention also relates to a pharmaceutical combination for use in a method for the treatment of cancer, the pharmaceutical combination comprising: (i) at least one metal ion, preferably selected in the group consisting of iron (Fe), copper (Cu), manganese (Mn), calcium (Ca), magnesium (Mg), zinc (Zn), and mixtures thereof; and (ii) hyaluronate (HA) or a hyaluronate conjugate, wherein said method comprises the simultaneous, separate or sequential administration of (i) and (ii) directly into the lymphatic system, preferably into a lymph node or a lymph vessel.
1-18. (canceled)
A method of treating cancer and/or immune deficiency diseases and/or infectious diseases comprising administering a pharmaceutical composition comprising a metal ion and optionally hyaluronate (HA) or a hyaluronate conjugate via intralymphatic administration of the pharmaceutical composition to a subject, wherein the metal ion is selected from the group consisting of iron (Fe), copper (Cu), manganese (Mn), calcium (Ca), magnesium (Mg), zinc (Zn), and mixtures thereof.
A method for the treatment of cancer and/or immune deficiency diseases and/or infectious diseases in a subject, comprising intralymphatic administration of a complex of hyaluronate or hyaluronate conjugate and at least one metal ion or a pharmaceutical composition comprising said complex and a pharmaceutically acceptable excipient and/or carrier, to the subject, wherein said hyaluronate presents a molecular weight between 1-10,000 kDa and said metal ion being selected from the group consisting of iron (Fe), copper (Cu), manganese (Mn), calcium (Ca), magnesium (Mg), zinc (Zn), and mixtures thereof.
A method for the treatment of cancer and/or immune deficiency diseases and/or infectious diseases comprising the administration of a pharmaceutical combination to a subject in need of treatment, said pharmaceutical combination comprising:
Dependencies are inferred from the claim text.